Clin Osteol 2003; 8(1): 4-5

Statins and bone metabolismArticles

R. Ištok, M. Stančíková, K. Švík, J. Rovensky

Reseach revealed that statins, inhibitors of 3-hydroxy-3-methylglutaryl CoA reductase, used in the treatment of hyperlipidaemia, can stimulate bone formation as well as inhibit bone resorption. Their mechanism of action on both osteoblasts and osteoclasts is most probably due to the inhibition of protein prenylation due to a lack of isoprenoid intermediate products of the mevalonate pathway inhibited by statins. So far,the results of clinical tri­ als that investigated the effect of statin administration on bone metabolism are highly contradictory. With systemic administration, only a small pro­ portion of the statins now used in the management of hyperlipidaemia reaches the bone. Only statins with better availability in bone tissue have a fu­ ture in the treatment of osteoporosis.

Keywords: statins, bone formation, bone resorption, osteoporosis

Published: June 11, 2003  Show citation

ACS AIP APA ASA Harvard Chicago Chicago Notes IEEE ISO690 MLA NLM Turabian Vancouver
Ištok R, Stančíková M, Švík K, Rovensky J. Statins and bone metabolism. Osteologický bulletin. 2003;8(1):4-5.
Share...
Download citation
  • BibTeX (.bib)
  • Bookends (.ris)
  • EasyBib (.ris)
  • EndNote (.enw)
  • EndNote 8 (.xml)
  • ISI WoS (.isi)
  • Medlars (.medlars)
  • Mendeley (.ris)
  • MODS (.xml)
  • Papers (.ris)
  • RefWorks (.txt)
  • RefManager (.ris)
  • RIS (.ris)
  • MS Word (.xml)
  • Zotero (.ris)
    • Open full article

    References

    1. Rogers MJ, Coxon FP. The mevalonate pathway in osteoclast signalling. Calcif Tissue Int 2002;70:242. Go to original source...
    2. Van Beek E, Lowik C, Van der Pluijm G et al.The role of geranylgeranylation in bone resorption and its supression by bisphosphonates in fetal bone explants in vit­ ro: A clue to the mechanism of action of nitrogen-containing bisphosphonates. J Bone Min Res 1999;14:722-729. Go to original source...
    3. Luckman SP, Hughes DE, Coxon FP et al. Nitrogen-containing bisphosphonates inhibit the mevalonate pathway and prevent post-translational prenylation of GTPbinding proteins, including Ras. J Bone Min Res 1998;13:581-589. Go to original source...
    4. Mundy G, Garett R, Harris S et al. Stimulation of bone formation in vitro and in rodents by statins. Science 1999;286:1946-1949. Go to original source...
    5. Maeda T, Matsunuma A, Kawane T et al. Simvastatin promotes osteoblast differentation and mineralization in MC3T3-E1 cells. Biochem Biophys Res Commun 2001;280:874-877. Go to original source...
    6. Sugiyama M, Kodama T, Konishi K et al. Compactin and simvastatin, but not pra­ vastatin, induce bone morphogenetic protein 2 in human osteosarcoma cells. Bio­ chem Biophys Res Commun 2000;271:688-692. Go to original source...
    7. Wilkie D, Bowman B, Lyga A et al. Cerivastatin increases cortical bone formati­ on in OVX rats. J Bone Min Res 2000;15,Suppl.:549.
    8. Oxlund H, Andreassen TT. Simvastatin given orally to adult rats increases the compressive strenght of vertebral bodies. J Bone Min Res 2000;15,Suppl.:549.
    9. Garrett IR, Esparza J, Chen D et al. Statins mediate their effect on osteoblasts by inhibition HMG-CoA reductase and ultimately BMP-2. J Bone Min Res 2000; 15,Suppl.:225.
    10. Chung YS, Lee MD, Lee SK et al. HMG-CoA reductase inhibitors increase BMD in type 2 diabetes mellitus patients. J Clin Endocrinol Metab 2000;85:1137-1142. Go to original source...
    11. Edwards CJ, Hart DJ, Spector TD. Oral statins and increased bone-mineral densi­ ty in postmenopausal women. Lancet 2000;355:2218-2219. Go to original source...
    12. Sirola J, Honkanen R, Kroger H et al. Relation of statin use and bone loss: A pro­ spective population-based cohort study in early postmenopausal women. Osteoporos Int 2002;13:537-541. Go to original source...
    13. Chan KA, Andrade SE, Boles M et al. Inhibitors of hydroxymethylglutaryl-coenzyme A reductase and risk of fracture among older women. Lancet 2000; 355:2185-2188. Go to original source...
    14. Wang PS, Solomon DH, Mogun H et al. HMG-CoA reductase inhibitors and the risk of hip fractures in elderly patients. JAMA 2000;283:3205-3210. Go to original source...
    15. Lacroix AZ, Cauley JA, Jackson R et al. Does statins use reduce risk of fracture in postmenopausal women? Results from the women's Health Iniciative Observa­ tional Study. J Bone Min Res 2000;15,Suppl.:155.
    16. Van Staa TP, Wegman SLJ, de Vries F et al. Use of statins and risk of fractures. J Bone Min Res 2000;15,Suppl.:155. Go to original source...

    Return to the content


    Clinical Osteology

    Madam, Sir,
    please be aware that the website on which you intend to enter, not the general public because it contains technical information about medicines, including advertisements relating to medicinal products. This information and communication professionals are solely under §2 of the Act n.40/1995 Coll. Is active persons authorized to prescribe or supply (hereinafter expert).
    Take note that if you are not an expert, you run the risk of danger to their health or the health of other persons, if you the obtained information improperly understood or interpreted, and especially advertising which may be part of this site, or whether you used it for self-diagnosis or medical treatment, whether in relation to each other in person or in relation to others.

    I declare:

    1. that I have met the above instruction
    2. I'm an expert within the meaning of the Act n.40/1995 Coll. the regulation of advertising, as amended, and I am aware of the risks that would be a person other than the expert input to these sites exhibited

    No
    Yes

    If your statement is not true, please be aware
    that brings the risk of danger to their health or the health of others.